Beam Therapeutics (BEAM) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026BEAM-302 and alpha-1 antitrypsin deficiency
BEAM-302 is in a pivotal accelerated-approval cohort; enrollment is swift, with the 50th dose expected in H1 2027, followed by 12 months of follow-up and a filing package.
Trial spans six countries and 15+ enrolling sites; screen failures are low and predictable, with similar recruitment rates in the U.S. and ex-U.S.
The intended pivotal population includes patients with lung disease, with or without liver involvement; more than 90% of patients fall within this broad label.
Reported data showed 90%+ corrected M protein, reduced Z protein and inducible expression; one infection case showed AAT rising from the mid-teens to 25 micromolar.
Additional updates are expected to include liver biopsies, BAL fluid, CT densitometry, FEV1 and patient-reported outcomes; no interim disclosure is planned for the 50-patient pivotal cohort.
Regulatory path and competitive position
FDA feedback calls for 12 months of pivotal follow-up; earlier engagement could be considered if data show a robust, stable benefit, but the current plan remains a 12-month dataset.
CT densitometry is the preferred confirmatory endpoint; SPARTA results expected by year-end 2026 may inform its use, while FEV1 and St. George's Respiratory Questionnaire remain alternatives.
Management described a multi-year lead in alpha-1 clinical experience and plans to build payer and site relationships; LNP delivery is viewed as scalable for broad treatment after launch.
Risto-cel and sickle cell opportunity
Risto-cel BLA writing is being finalized, with filing on track for December 2026; approval could come in Q3 2027 with Priority Review or December 2027 under standard review.
Management cited projected 2026 sales above $700M for the two marketed sickle cell gene therapies and forecast a $1B+ category starting in 2027.
Risto-cel differentiation includes 60% fetal hemoglobin and 40% sickle hemoglobin, faster engraftment by several days, full anemia resolution and median single-round mobilization in BEACON.
Commercial preparation includes patient-journey tracking, hospital coordination and a modest field footprint focused on large U.S. centers.
Latest events from Beam Therapeutics
- Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update